Inflammatory bowel diseases (IBD) - Critical discussion of etiology, pathogenesis, diagnostics, and therapy;Chronisch entzündliche darmerkrankungen - Kritische diskussion von ätiologie, pathogenese, diagnostik und therapie

Radiologe

Volumn 43, Issue 1, 2003, Pages 1-8

  Ochsenkuhn T ^a   Sackmann, M ^a   Goke B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Crohn's disease; Diagnostics; Review; Therapy; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE;

ARTICLE; BARIUM ENEMA; CIGARETTE SMOKING; CROHN DISEASE; DIAGNOSTIC VALUE; ENDOSCOPY; ENTERITIS; ENVIRONMENTAL FACTOR; HUMAN; IMMUNE RESPONSE; INTESTINE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREVALENCE; RADIODIAGNOSIS; RISK FACTOR; ULCERATIVE COLITIS;

EID: 0038287485     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00117-002-0844-9     Document Type: Article

References (42)

1. Sheffield BF, Carney MW (1976) Crohn's disease: a psychosomatic illness? Br J Psychiatry 128:446-450
2. Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347:417-429
3. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TIA, Binder V (1991) Familial occurrence of inflammatory bowel disease. N Engl J Med 324:84-88
4. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B (1988) Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: a study of heritability and the influence of smoking. Gut 29:990-996
5. Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. (1996) Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379:821-823
6. Hugot JP, Chamaillard M, Zouali H et al.(2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603
7. Ogura Y, Bonen DK, Inohara N et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606
8. Schmitz H, Barmeyer C, Fromm M et al. (1999) Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 116:301-309
9. Schnitzler F, Göke B, Ochsenkühn T et al. (2002) CARD15 mutations in a Munich cohort of IBD-patients. Gut 51 [suppl III]:A130
10. Andersson RE, Olaison G, Tysk C, Ekbom A (2001) Appendectomy and protection against ulcerative colitis. N Engl J Med 344:808-814
11. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM (1997) Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 40:619-622
12. Cosnes J, Beaugerie L, Carbornnel F, Gendre JP (2001) Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 120:1093-1099
13. Rath HC, Schultz M, Freitag R et al. (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 69:2277-2285
14. Seibold F, Egger B, Göke B (2000) Neues von der Pathogenese der chronisch entzündlichen Darmerkrankungen: Was haben wir von Colitis-Tiermodellen gelernt? Schweiz Med Wochenschr 130:749-755
15. Ostro MJ, Greenberg GR, Jeejeebhoy KN (1985) Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. JPEN J Parenter Enteral Nutr 9:280-287
16. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G (1991) Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338:771-774
17. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11:853-858
18. Mashimo H, Wu DC, Podolsky DK, Fishman MC (1996) Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274:262-265
19. Fuss IJ, Neurath M, Boirivant M et al. (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261-1270
20. Ochsenkühn T, Sackmann M, Göke B (2002) Infliximab in the treatment of fulminant and severe ulcerative colitis. Gut 51 [suppl III]:A 48
21. Ochsenkühn T, Holzknecht N, Reiser M, Göke B, Sackmann M (2001) Inflammation of the jejunum in Crohn's disease: detection by MRI-enteroclysis. Gastroenterology 120 [suppl 1]:A271-A271
22. Miner PB (2000) Clinical features, course, laboratory findings, and complications in ulcerative colitis. In: Kirsner JB (ed) Inflammatory bowel disease, 5th ed. Saunders, Philadelphia, pp 299-304
23. Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, Herfarth C, Heuschen G (2001) Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 120:841-847
24. Riddell RH (2000) Pathology of idiopathic inflammatory bowel disease. In: Kirsner JB (ed) Inflammatory bowel disease, 5th ed. Saunders, Philadelphia, pp 427-450
25. Oberhuber G, Puspok A, Oesterreicher C, Novacek G, Zauner C, Burghuber M, Vogelsang H, Potzi R, Stolte M, Wrba F (1997) Focally enhanced gastritis: a frequent type of gastritis in patients with Crohn's disease. Gastroenterology 112:698-706
26. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF (2002) The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122:1242-1247
27. Marion JF, Rubin PH and Present DH (2000) Differential diagnosis in ulcerative colitis and Crohn's disease. In: Kirsner JB (ed) Inflammatory bowel disease, 5th ed. Saunders, Philadelphia, pp 315-325
28. Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs HJ (2002) Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 12:1416-1422
29. Ell C, Remke S,May A, Helou L, Henrich R, Mayer G (2002) The first prospective controlled trial comparing wireless capsule endoscopy with push enteroscopy in chronic gastrointestinal bleeding. Endoscopy 34:685-689
30. Duchmann R, Lochs H, Kruis W (1999) Crohn's disease, ulcerative colitis. When bacteria attack the intestinal wall. MMW Fortschr Med 141:48-51
31. Simms L et al. (2001) Budesonide for maintenance of remission in Crohn's disease (Cochrane Review). The Cochrane Library 4. Oxford, Update Software
32. Steinhart AH et al. (2001) Corticosteroids for maintaining remission of Crohn's disease (Cochrane Review). The Cochrane Library 4. Oxford, Update Software
33. Singleton JW et al.(1979) National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 77:870-882
34. Rutgeerts PJ (2001) The limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 15:1515-1525
35. Stange EF et al. (1997) Therapy of Crohn's disease results of a Consensus Conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 35:541-554
36. Sandborn W et al. (2001) Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease (Cochrane Review). The Cochrane Library 4. Oxford, Update Software
37. Pearson DC et al. (2001) Azathioprine for maintaining remission of Crohn's disease (Cochrane Review). In: The Cochrane Library 4. Oxford, Update Software
38. Kirk AP et al. (1982) Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 284:1291-1292
39. Sandborn WJ (2001) Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg 64:201-204
40. Lewis JD et al. (2000) Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118:1018-1024
41. Lewis JD et al. (2001) Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121:1080-1087
42. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA (2001) An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 7:181-189